Weekly Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Corporate Logo
During 2018 Q2 the big money sentiment decreased to 1.3. That’s change of 0.53, from 2018Q1’s 1.83. 24 investors sold all, 45 reduced holdings as Amicus Therapeutics, Inc. ratio is negative. 61 grew holdings while 29 funds acquired holdings. Funds hold 216.23 million shares thus 0.98% more from 2018Q1’s 214.13 million shares.
First Advsrs Limited Partnership reported 184,350 shs stake. Raymond James & Associates reported 55,161 shs stake. Invesco accumulated 4.36 million shs or 0.02% of the stock. Bancorporation Of America De reported 0% of its capital in Amicus Therapeutics, Inc. (NASDAQ:FOLD). 98,031 are owned by Federated Incorporated Pa. Vanguard Group Inc holds 16.27 million shs. Tcw Grp has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Ameriprise Incorporated owns 0.02% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 2.60 million shs. Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 11,925 shs. Rhumbline Advisers invested in 0.01% or 183,812 shs. American Intll Gru reported 123,320 shs stake. Moreover, Parallax Volatility Advisers Ltd Partnership has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Neuberger Berman Grp Inc Ltd Llc holds 0% or 90,000 shs in its capital. Sg Americas Ltd Liability holds 10,308 shs. Connecticut-based Point72 Asset Management Lp has invested 0.04% in Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Amicus Therapeutics, Inc. registered $8.07 million net activity with 4 insider buys and 3 selling transactions since July 2, 2018. On Monday, July 2 Baird William D III also sold $156,292 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD). On Monday, July 2 Andrews Kurt J. had sold 5,000 shs worth $78,166.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

In total 2 analysts cover Amicus Therapeutics (NASDAQ:FOLD). “Buy” rating has 0, “Sell” are 0, while 2 are “Hold”. (NASDAQ:FOLD) has 0 bullish analysts. 2 are the (NASDAQ:FOLD)’s ratings reports on Dec 8, 2018 according to StockzIntelligence Inc. On Friday, August 17 the stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Neutral” rating by Chardan Capital Markets. Listed here are Amicus Therapeutics, Inc. (NASDAQ:FOLD) PTs and latest ratings.

29/10/2018 Broker: Citigroup Rating: Neutral New Target: $12 Initiates Coverage On
17/08/2018 Broker: Chardan Capital Markets Old Rating: Buy New Rating: Neutral Old Target: $18.5 New Target: $15 Downgrade

FOLD hit $9.92 during the last trading session after $0.44 change.Currently Amicus Therapeutics, Inc. is downtrending after 10.62% change in last December 8, 2017. FOLD has also 2.45M shares volume. The stock underperformed the S&P500 by 26.24%.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases.The firm is worth $1.88 billion. The Company’s principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies.Last it reported negative earnings. The firm is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease.

For more Amicus Therapeutics, Inc. (NASDAQ:FOLD) news released recently go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “5 Reasons That Make Methanex (MEOH) Stock a Solid Choice Now – Nasdaq” released on November 15, 2018, “Why Is Brighthouse Financial (BHF) Down 11.9% Since Last Earnings Report? – Nasdaq” on December 05, 2018, “Digital newcomers out to disrupt South African banking – Nasdaq” with a publish date: December 04, 2018, “Nasdaq Launches US Corporate Bond Exchange – Nasdaq” and the last “Trinseo (TSE) Earnings and Revenues Beat Estimates in Q3 – Nasdaq” with publication date: November 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.